Analytical Data
-
Gene name
IL-18BP
- Application
-
Alternative Names
IL18BPa; MC51L-53L-54L Homolog Gene Product; Tadekinig-alfa
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
> 95% as determined by SDS-PAGE.
-
Uniprot
Q9JLN2
-
Expression Region
Thr29~Pro193
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-18 binding protein (IL-18BP) is a crucial regulatory molecule involved in the immune response, primarily through its role in modulating the activity of interleukin-18 (IL-18), a cytokine that promotes inflammation and immune responses. The excessive activation of IL-18 can lead to various inflammatory diseases and conditions, including autoimmune disorders, chronic inflammatory diseases, and certain cancers. Consequently, the study of IL-18BP has garnered significant attention as a potential therapeutic target for treating these conditions. IL-18BP can inhibit IL-18 activity by binding to it and preventing its interaction with the IL-18 receptor, thereby regulating inflammatory responses. Researchers have been exploring recombinant forms of IL-18BP to assess its efficacy and safety as a therapeutic agent. Beyond its role in inflammation, IL-18BP also provides insights into the complex interplay between cytokines in the immune system. Understanding the structure-function relationship of IL-18BP and its mechanisms of action can lead to the development of innovative treatments that effectively control excessive inflammatory responses while preserving important immune functions. Ongoing studies are also investigating the potential of IL-18BP in combination therapies, which could enhance patient outcomes in various inflammatory and autoimmune diseases.
